- Home
- GGT vs CLLS Comparison
GGT vs CLLS Comparison
Compare GGT & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGT
- CLLS
- Stock Information
- Founded
- GGT 1994
- CLLS 1999
- Country
- GGT United States
- CLLS France
- Employees
- GGT N/A
- CLLS N/A
- Industry
- GGT Trusts Except Educational Religious and Charitable
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- GGT Finance
- CLLS Health Care
- Exchange
- GGT Nasdaq
- CLLS Nasdaq
- Market Cap
- GGT 128.7M
- CLLS 144.4M
- IPO Year
- GGT N/A
- CLLS 2007
- Fundamental
- Price
- GGT $4.06
- CLLS $1.49
- Analyst Decision
- GGT
- CLLS Buy
- Analyst Count
- GGT 0
- CLLS 3
- Target Price
- GGT N/A
- CLLS $6.67
- AVG Volume (30 Days)
- GGT 59.7K
- CLLS 48.8K
- Earning Date
- GGT 01-01-0001
- CLLS 05-12-2025
- Dividend Yield
- GGT 15.56%
- CLLS N/A
- EPS Growth
- GGT N/A
- CLLS N/A
- EPS
- GGT 0.83
- CLLS N/A
- Revenue
- GGT N/A
- CLLS $54,747,000.00
- Revenue This Year
- GGT N/A
- CLLS $48.52
- Revenue Next Year
- GGT N/A
- CLLS $5.17
- P/E Ratio
- GGT $6.90
- CLLS N/A
- Revenue Growth
- GGT N/A
- CLLS 351.26
- 52 Week Low
- GGT $4.32
- CLLS $1.10
- 52 Week High
- GGT $7.00
- CLLS $2.81
- Technical
- Relative Strength Index (RSI)
- GGT 32.21
- CLLS 53.80
- Support Level
- GGT $3.98
- CLLS $1.46
- Resistance Level
- GGT $4.16
- CLLS $1.60
- Average True Range (ATR)
- GGT 0.07
- CLLS 0.08
- MACD
- GGT -0.01
- CLLS -0.01
- Stochastic Oscillator
- GGT 19.05
- CLLS 65.26
About GGT Gabelli Multi-Media Trust Inc. (The)
Gabelli Multimedia Trust Inc is a non-diversified closed-end management investment company. Its investment objective is the long-term growth of capital with income as a secondary objective. The fund invests majority of its assets, under normal market conditions, in common stock and other securities, including convertible securities, preferred stock, options, and warrants of companies in the telecommunications, media, publishing, and entertainment industries.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.